<DOC>
	<DOCNO>NCT02029911</DOCNO>
	<brief_summary>This multi-center , single-arm , non-randomized , prospective clinical study . The clinical study design non-inferiority study ass effectiveness Aurora Endometrial Ablation System compare objective standard . Safety evaluate determine number percentage subject experience one serious adverse event .</brief_summary>
	<brief_title>A Multi-Center , Single Arm Clinical Study Safety Efficacy AURORA™ Endometrial Ablation System</brief_title>
	<detailed_description />
	<mesh_term>Menorrhagia</mesh_term>
	<criteria>1 . Refractory menorrhagia definable organic cause 2 . Female subject age 25 50 year 3 . Uterine sound measurement 6.0cm 10.0cm ( external o internal fundus ) 4 . One follow criterion : A. Documented history menorrhagia secondary dysfunctional uterine bleeding ( DUB ) . B . If pictorial blood loss assessment chart ( PBLAC ) score system use ; minimum PBLAC score ≥150 1 month prior study enrollment . 5 . Premenopausal enrollment determine FSH measurement ≤ 40 IU/ml 6 . Not pregnant desire pregnant future 7 . Patient agree use hormonal contraception medical intervention bleeding study 8 . Able provide write informed consent use form approve review IRB/EC 9 . Subject agree followup exam data collection , include ability accurately use menstrual diary PBLAC analysis . 10 . Subject literate demonstrate understanding use menstrual diary . 1 . Pregnancy subject desire conceive 2 . Endometrial hyperplasia confirm histology 3 . Presence active endometritis 4 . Active pelvic inflammatory disease 5 . Active sexually transmit disease ( STD ) , time ablation . Note : Treatment STD document chart serf sufficient evidence infection resolution . Patient may consider study enrollment . 6 . Presence bacteremia , sepsis , active systemic infection 7 . Active infection genitals , vagina , cervix , uterus urinary tract time procedure 8 . Known/suspected gynecological malignancy within past 5 year 9 . Known clot defect bleed disorder 10 . Untreated/unevaluated cervical dysplasia ( except CIN I ) 11 . Known/suspected abdominal/pelvic cancer 12 . Prior uterine surgery ( except low segment cesarean section ) interrupt integrity uterine wall ( e.g. , myomectomy classical cesarean section ) 13 . Previous endometrial ablation procedure 14 . Currently medication could thin myometrial muscle , longterm steroid use ( except inhaler nasal therapy asthma ) 15 . Currently anticoagulants 16 . Abnormal obstruct cavity confirm hysteroscopy SIS , specifically : 1 . Septate bicornuate uterus congenital malformation uterine cavity 2 . Pedunculated submucosal myoma distort uterine cavity 3 . Polyps likely cause subject 's menorrhagia 4 . Intramural subserosal myoma distort uterine cavity 17 . Presence intrauterine device ( IUD ) patient unwilling remove time operative visit 18 . Presence implantable contraceptive device ( e.g . Essure Adiana ) . 19 . Subject currently hormonal birth control therapy unwilling use nonhormonal birth control postablation ( include Mirena device ) . 20 . Subject within 6weeks post partum . 21 . Any general health condition , opinion Investigator , could represent increase risk subject 22 . Any subject currently participate considers future participation research investigational drug device .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Menorrhagia</keyword>
	<keyword>Excessive uterine bleeding</keyword>
	<keyword>Endometrial Ablation</keyword>
</DOC>